Increased Drug Pricing Transparency and 340B Program Accountability
This act introduces a two-year pause on new hospital registrations in the 340B drug discount program to clarify eligibility rules and enhance transparency. Citizens can expect better insight into how hospitals utilize these discounts and whether they provide adequate charity care, potentially impacting drug access and costs.
Key points
Two-year moratorium on new hospital registrations in the 340B drug discount program to establish clear rules.
Mandatory labeling of 340B-purchased drugs in billing systems (Medicare, Medicaid) to increase price transparency.
Hospitals will be required to report annual revenues and costs related to 340B discounted drugs, as well as charity care data.
More information on how hospitals use drug discounts will be publicly available, potentially affecting patient awareness.
Expired
Citizen Poll